: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis

CompletedPhase 4MS (type not specified)2005-003903-35

What it found

No results found

We found no results in the registry or in papers.

What was tested

Treatment tested

  • Levetiracetam

    Synaptic vesicle glycoprotein 2A modulator|Voltage-gated N-type calcium channel alpha-1B subunit blocker

What it measured

Main measures

  • An objective measure of tremor will be performed using an accelerometer which will be attached to the limb under investigation, providing a sensitive measure of oscillatory movement. EMG will be recorded from muscles using adhesive surface electrodes, allowing direct measurement of oscillatory patterns of muscle activation. The amplitude of power spectral peaks in EMG and acceleration will provide

    Arm and hand functionPhysical function

Who could take part

MS (type not specified)

Show the full criteria

Inclusion criteria

Inclusion: 1. McDonald criteria for diagnosis of MS (McDonald, 2001)16 Exclusion: 1. There is evidence of a further significant MS relapse during the trial

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

To determine whether Keppra can be used to reduce tremor in patients suffering from Multiple Sclerosis.

Loading reviews and guidelines…

Related trials

History

    1. Started

      Dec 2005

    Assembled by software from public sources.